Skip to main content

Danazol Disease Interactions

There are 8 disease interactions with danazol.

Major

Danazol (applies to danazol) abnormal uterine bleeding

Major Potential Hazard, High plausibility.

The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present. Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) androgen dependent tumors

Major Potential Hazard, Moderate plausibility. Applicable conditions: Prostate Tumor

The use of danazol is contraindicated in patients with androgen- dependent tumors.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

The use of danazol is contraindicated in patients with severe hepatic impairment. Danazol is metabolized by the liver to inactive forms. Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction. Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) impaired cardiac function

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Danazol is contraindicated in patients with marked impaired cardiac function.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) intracranial hypertension

Major Potential Hazard, High plausibility.

Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral or papilledema and/or intracranial hypertension.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) porphyria

Major Potential Hazard, High plausibility.

The use of danazol is contraindicated in patients with porphyria. Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) thromboembolic disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding, History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals
Major

Danazol (applies to danazol) volume overload/renal impairment

Major Potential Hazard, High plausibility. Applicable conditions: Fluid Retention, Renal Dysfunction, Seizures, Diabetes Mellitus, Hypertension, Congestive Heart Failure, Migraine

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

References

  1. (2001) "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals

Danazol drug interactions

There are 252 drug interactions with danazol.

Danazol alcohol/food interactions

There is 1 alcohol/food interaction with danazol.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer